Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company leveraging biomarkers and augmented intelligence to identify pain sources in chronic low back pain, announced the addition of Lanman Spinal Neurosurgery as a clinical site in its CLARITY trial. Based in Beverly Hills, this private practice is recognized for its expertise in complex spinal procedures and early adoption of innovative technologies. The inclusion marks a strategic expansion beyond academic medical centers, reflecting growing interest in integrating Aclarion's Nociscan platform into real-world workflows.
The CLARITY trial is a prospective, randomized, multi-center study evaluating Nociscan in 300 patients undergoing surgical treatment for discogenic low back pain. The primary endpoint is change in back pain measured on a 100mm VAS at 12 months. Aclarion anticipates an initial internal data readout and public disclosure of early interim results in Q4 2026. Nociscan uses MR Spectroscopy to quantify chemical biomarkers associated with disc pain, providing insights that standard MRI cannot. When all Nociscan-positive discs are treated, the technology demonstrates a 97% surgical success rate.
"I have spent more than 25 years practicing spinal surgery in Beverly Hills, and my perspective is shaped not only by that experience, but also by having undergone multiple spine surgeries myself," said Dr. Todd Lanman, founder of Lanman Spinal Neurosurgery. "We have made significant progress in moving beyond one-size-fits-all solutions for low back pain. Nociscan introduces a new layer of clarity by leveraging MR Spectroscopy to identify pain-generating discs. The CLARITY trial is particularly important because it is designed to evaluate how this technology can enhance clinical decision-making. This ability to match the right procedure to the right patient is what moves the field forward."
Chronic low back pain affects approximately 266 million people worldwide. Ryan Bond, Chief Strategy Officer of Aclarion, emphasized the significance of this expansion: "Private practice spine surgeons play a critical role in treating the majority of patients suffering from chronic low back pain, and the inclusion of Lanman Spinal Neurosurgery reflects the growing demand for more precise, data-driven tools in everyday clinical practice. Dr. Lanman is widely recognized for his commitment to innovation and patient-centered care, and we are excited to partner with his team as we continue to expand CLARITY and generate the high-quality evidence needed to advance Nociscan."
For more information about CLARITY, visit the CLARITY Trial page. To find a Nociscan center, view the site map.
